

**Food and Drug Administration**  
Center for Drug Evaluation and Research

Oncologic Drugs Advisory Committee Meeting  
March, 13, 2006

BIBLIOGRAPHY

MORNING SESSION

DeGeorge, JJ., et. al. (1998). Regulatory Considerations for Preclinical Development of Anticancer Drugs. *Cancer Chemotherapy Pharmacology*. 41: 173-185.

Farrell, A.T., et. al. (2003). How Oncology Drug Development Differs from Other Fields. In *Handbook of Anticancer Drug Development*. Budman, DR., Calvert, AH., Rowinsky, EK (eds). Lippincott Williams & Wilkens, Baltimore, MD. pp 3-10.

Horstmann E., et. al. (2005). Risks and Benefits of Phase I Oncology Trials, 1991 through 2002. *N Eng J Med* 352 (9): 895-904.

Therasse P., et. al. (2000). New Guidelines to Evaluate the Response to Treatment in Solid Tumor. *J. Natl Cancer Institute* 92: 205-216.

**Food and Drug Administration**  
Center for Drug Evaluation and Research

Oncologic Drugs Advisory Committee Meeting  
March, 13, 2006

Bibliography

AFTERNOON SESSION

DuBois, A., et. al. (2005) 2004 Consensus Statements on the Management of Ovarian Cancer: Final Document of the 3<sup>rd</sup> International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIIG OCCC 2004). *Annals of Oncology* 16: vii7-vii12.

Vermorken, J.B., et al (2005). Clinical Trials in Ovarian Carcinoma: Study Methodology. *Annals of Oncology* 16 (8): vii20-vii29.